WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

Firm News

On September 19, 2017, Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing. The round was led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures. Disarm was co-founded, seeded and incubated in 2016 by Atlas Venture, together with Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis.

Stuart Falber led the WilmerHale team representing Disarm in this transaction, which also included Stephanie Singer and Brett Bromann.

Read Disarm's press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.